BackEpizyme Overview

Epizyme Total Assets

Latest total assets for EPZM: $260M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$264.16M
↓ 25.07% YoYΔ $-88.39M vs prior year quarter

Peer trimmed avg / median

Loading

Epizyme Total Assets History

Loading

Epizyme vs. peers: Total Assets Comparison

Loading

Epizyme Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Epizyme (EPZM) FAQ

As of the most recent data (June 2022), EPZM shows a total assets of $260M. That compares with $350M in the prior-year period — down 25.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EPZM's total assets is now $260M (was $350M) — a 25.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Epizyme is outperforming or lagging.

Tracking EPZM's total assets over time shows whether Epizyme is scaling, shrinking, or reshaping that part of the business. The current reading is $260M That compares with $350M in the prior-year period — down 25.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Epizyme's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $260M) with ownership activity and broader fundamentals.

Epizyme's total assets is $260M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.